A peptide-engineered alginate aerogel with synergistic blood-absorbing and platelet-binding capabilities to rapidly stop bleeding.

Polysaccharide matrix infused with hemostasis-stimulating chemistry represents a critical medical need of bleeding management. Herein, we describe the development of a polysaccharide-peptide conjugate platform, an alginate engineered with fibrinogen-derived platelet-binding peptides (APE). The alginate backbone was found to allow for multivalent grafting of the peptides. Processing APE conjugate into crosslinked aerogels promoted platelet accumulation, leading to a significant reduction in the coagulation time of whole rabbit blood and improving the stability of the formed clot. The APE aerogels also exhibited a high porosity and fluid uptake capacity (>90 in weight ratio) as well as good biocompatibility in hemostasis. Furthermore, in vivo studies conducted in rat models of tail cut and hepatic hemorrhage showed that APE aerogels reduced bleeding time by >58 % and blood loss by >61 %. The platelet-enrichment capacity of the APE construct synergized by high absorbency in its aerogel form offers a prototype for customized polysaccharide hemostats.